-
August 16, 2016PREVIEW
Addition of liraglutide (Victoza—Novo Nordisk) to standard of care therapy in patients with type 2 diabetes at high risk for cardiovascular (CV) events resulted in a reduced risk of adverse CV...
-
June 28, 2016PREVIEW
The risk of hypoglycemia increases substantially when a dipeptidyl peptidase-4 (DPP-4) inhibitor is given with a sulfonylurea, emphasizing the need to reduce the sulfonylurea dose and educate...
-
June 14, 2016PREVIEW
Long-term exposure of testosterone replacement therapy was associated with a lower risk of death, cardiovascular (CV) events, and prostate cancer, whereas shorter durations of therapy increased...
-
March 2, 2016PREVIEW
The American Diabetes Association (ADA) has released new guidance on management of diabetes for residents in long-term care or skilled nursing facilities that focuses on simplified treatment...
-
March 2, 2016PREVIEW
Given the potential benefits and harms of long-term use of bisphosphonate therapy for the management of osteoporosis, the American Society for Bone and Mineral Research (ASBMR) released guidance...
Pages
